Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

The HIV protease inhibitor saquinavir inhibits HMGB1 driven inflammation by targeting the interaction of cathepsin V with TLR4/MyD88.

Pribis JP, Al-Abed Y, Yang H, Gero D, Xu H, Montenegro MF, Bauer EM, Kim S, Chavan SS, Cai C, Li T, Szoleczky P, Szabo C, Tracey KJ, Billiar TR.

Mol Med. 2015 Sep 2. doi: 10.2119/molmed.2015.00197. [Epub ahead of print]

2.

Insights into the Interactions of Fasciola hepatica Cathepsin L3 with a Substrate and Potential Novel Inhibitors through In Silico Approaches.

Hernández Alvarez L, Naranjo Feliciano D, Hernández González JE, Soares RO, Barreto Gomes DE, Pascutti PG.

PLoS Negl Trop Dis. 2015 May 15;9(5):e0003759. doi: 10.1371/journal.pntd.0003759. eCollection 2015 May. Erratum in: PLoS Negl Trop Dis. 2015 Jun;9(6):e0003856. Soares, Rosemberg de Oliveira [corrected to Soares R O].

3.

A molten globule-to-ordered structure transition of Drosophila melanogaster crammer is required for its ability to inhibit cathepsin.

Tseng TS, Cheng CS, Chen DJ, Shih MF, Liu YN, Hsu ST, Lyu PC.

Biochem J. 2012 Mar 15;442(3):563-72. doi: 10.1042/BJ20111360.

4.

Cathepsin L activity is essential to elastase perfusion-induced abdominal aortic aneurysms in mice.

Sun J, Sukhova GK, Zhang J, Chen H, Sjöberg S, Libby P, Xiang M, Wang J, Peters C, Reinheckel T, Shi GP.

Arterioscler Thromb Vasc Biol. 2011 Nov;31(11):2500-8. doi: 10.1161/ATVBAHA.111.230201.

5.

Cysteinyl cathepsins and mast cell proteases in the pathogenesis and therapeutics of cardiovascular diseases.

Qin Y, Shi GP.

Pharmacol Ther. 2011 Sep;131(3):338-50. doi: 10.1016/j.pharmthera.2011.04.010. Epub 2011 May 12. Review.

6.

Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.

Lucumi E, Darling C, Jo H, Napper AD, Chandramohanadas R, Fisher N, Shone AE, Jing H, Ward SA, Biagini GA, DeGrado WF, Diamond SL, Greenbaum DC.

Antimicrob Agents Chemother. 2010 Sep;54(9):3597-604. doi: 10.1128/AAC.00431-10. Epub 2010 Jun 14.

7.

A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells.

Shah PP, Wang T, Kaletsky RL, Myers MC, Purvis JE, Jing H, Huryn DM, Greenbaum DC, Smith AB 3rd, Bates P, Diamond SL.

Mol Pharmacol. 2010 Aug;78(2):319-24. doi: 10.1124/mol.110.064261. Epub 2010 May 13.

8.

Design, synthesis and biological evaluation of a library of thiocarbazates and their activity as cysteine protease inhibitors.

Liu Z, Myers MC, Shah PP, Beavers MP, Benedetti PA, Diamond SL, Smith AB 3rd, Huryn DM.

Comb Chem High Throughput Screen. 2010 May;13(4):337-51.

9.
11.

Molecular docking of cathepsin L inhibitors in the binding site of papain.

Beavers MP, Myers MC, Shah PP, Purvis JE, Diamond SL, Cooperman BS, Huryn DM, Smith AB 3rd.

J Chem Inf Model. 2008 Jul;48(7):1464-72. doi: 10.1021/ci800085c. Epub 2008 Jul 4. Erratum in: J Chem Inf Model. 2010 Dec 27;50(12):2274.

12.

Design, synthesis, and evaluation of inhibitors of cathepsin L: Exploiting a unique thiocarbazate chemotype.

Myers MC, Shah PP, Beavers MP, Napper AD, Diamond SL, Smith AB 3rd, Huryn DM.

Bioorg Med Chem Lett. 2008 Jun 15;18(12):3646-51. doi: 10.1016/j.bmcl.2008.04.065. Epub 2008 May 1.

Supplemental Content

Support Center